Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muna Al Jufairi

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Therapeutics and Clinical Risk Management|June 16, 2022
Cumulative Doses Predict the Risk of Furosemide-Induced Electrolyte Abnormalities in Critically Ill NeonatesKannan Sridharan, Abdulraoof Al Madhoob, Muna Al Jufairi
The International Journal of Risk & Safety in Medicine|March 1, 2021
Off-label drug use and the risk of medication errors in critically ill neonates: A conceptual pilot studyKannan Sridharan, Muna Al Jufairi, Eman Al Ansari
Current Drug Metabolism|May 13, 2020
Dose Optimization of Gentamicin in Critically Ill NeonatesKannan Sridharan, Muna Al Jufairi, Ali Mohamed Qader, et al.
Pediatric Investigation|June 16, 2023
Is fat-free mass-based gentamicin dosing regimen preferable than whole-body weight in neonates?Kannan Sridharan, Muna Al Jufairi, Eman Al Ansari, et al.
Current Drug Metabolism|March 6, 2024
Comparative Analysis of Machine Learning Algorithms Evaluating the Single Nucleotide Polymorphisms of Metabolizing Enzymes with Clinical Outcomes Following Intravenous Paracetamol in Preterm Neonates with Patent Ductus ArteriosusKannan Sridharan, George Priya Doss C, Hephzibah Cathryn R, et al.
Anaesthesiology Intensive Therapy|February 24, 2021
Drug utilisation in adult, paediatric and neonatal intensive care units, with an emphasis on systemic antimicrobialsKannan Sridharan, Hasan Hasan, Muna Al Jufairi, et al.
Journal of Pharmacy & Bioallied Sciences|July 20, 2023
Gentamicin in Neonates with Hemodynamically Significant Patent Ductus ArteriosusKannan Sridharan, Abdulraoof Al Madhoob, Muna Al Jufairi, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 16, 2021
Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent ductus arteriosusKannan Sridharan, Muna Al Jufairi, Eman Al Ansari, et al.
Journal of Clinical Pharmacy and Therapeutics|February 27, 2021
Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective studyKannan Sridharan, Muna Al Jufairi, Eman Al Ansari, et al.
Expert Opinion on Drug Safety|August 10, 2020
Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonatesKannan Sridharan, Hasan Msn Hasan, Muna Al Jufairi, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Therapeutics and Clinical Risk Management|June 16, 2022
Cumulative Doses Predict the Risk of Furosemide-Induced Electrolyte Abnormalities in Critically Ill NeonatesKannan Sridharan, Abdulraoof Al Madhoob, Muna Al Jufairi
The International Journal of Risk & Safety in Medicine|March 1, 2021
Off-label drug use and the risk of medication errors in critically ill neonates: A conceptual pilot studyKannan Sridharan, Muna Al Jufairi, Eman Al Ansari
Current Drug Metabolism|May 13, 2020
Dose Optimization of Gentamicin in Critically Ill NeonatesKannan Sridharan, Muna Al Jufairi, Ali Mohamed Qader, et al.
Pediatric Investigation|June 16, 2023
Is fat-free mass-based gentamicin dosing regimen preferable than whole-body weight in neonates?Kannan Sridharan, Muna Al Jufairi, Eman Al Ansari, et al.
Current Drug Metabolism|March 6, 2024
Comparative Analysis of Machine Learning Algorithms Evaluating the Single Nucleotide Polymorphisms of Metabolizing Enzymes with Clinical Outcomes Following Intravenous Paracetamol in Preterm Neonates with Patent Ductus ArteriosusKannan Sridharan, George Priya Doss C, Hephzibah Cathryn R, et al.
Anaesthesiology Intensive Therapy|February 24, 2021
Drug utilisation in adult, paediatric and neonatal intensive care units, with an emphasis on systemic antimicrobialsKannan Sridharan, Hasan Hasan, Muna Al Jufairi, et al.
Journal of Pharmacy & Bioallied Sciences|July 20, 2023
Gentamicin in Neonates with Hemodynamically Significant Patent Ductus ArteriosusKannan Sridharan, Abdulraoof Al Madhoob, Muna Al Jufairi, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 16, 2021
Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent ductus arteriosusKannan Sridharan, Muna Al Jufairi, Eman Al Ansari, et al.
Journal of Clinical Pharmacy and Therapeutics|February 27, 2021
Intravenous acetaminophen (at 15 mg/kg/dose every 6 hours) in critically ill preterm neonates with patent ductus arteriosus: A prospective studyKannan Sridharan, Muna Al Jufairi, Eman Al Ansari, et al.
Expert Opinion on Drug Safety|August 10, 2020
Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonatesKannan Sridharan, Hasan Msn Hasan, Muna Al Jufairi, et al.
Pageof 2